Biotechnology
Bristol Myers Squibb is a leading innovator in oncology that owns RayzeBio, a dynamic biotechnology company focused on developing transformative radiopharmaceutical therapies for cancer patients. RayzeBio harnesses the power of targeted radioisotopes to improve survival outcomes for people with cancer, with its lead asset RYZ101 currently in Phase 3 testing for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and earlier-stage testing for small cell lung cancer, breast cancer, and hepatocellular carcinoma. Operating as a standalone subsidiary within BMS, RayzeBio maintains its nimble biotech culture while leveraging the global expertise and best-in-class oncology capabilities of its parent company. The company aims to be the global leader in radiopharmaceuticals, blending the pioneering spirit of an emergent biotech with the resources of a major pharmaceutical innovator.
Industry
Biotechnology
Company Size
51-200 employees
Founded
2020
Beta · Sourced from candidate reports
Be the first to share your experience with Bristol Myers Squibb.
Your reply helps other candidates know what to expect.
